Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells

27 Nov 2023

Abstract excerpt

BACKGROUND: Acute myeloid leukemia (AML) is a clonal malignant disorder which originates from a small number of leukemia-initiating cells or leukemic stem cells (LSCs)-the subpopulation that is also the root cause of relapsed/refractory AML. Chimeric antigen receptor (CAR)-T cell therapy has proved successful at combating certain hematologic malignancies, but has several hurdles that limit its widespread...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Pluripotent Stem Cells Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38012684
DOI: 10.1186/s12935-023-03153-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cellsPMID 38012684Read ↗

From induced pluripotent stem cell (iPSC) to universal immune cells: literature review of advances in a new generation of tumor therapiesSemantic proximity Read ↗

An Alternative Cell Therapy for Cancers: Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer CellsSemantic proximity Read ↗

Multiplexed iPSC platform for advanced NK cell immunotherapiesSemantic proximity Read ↗

Engineered iPSC ‐derived natural killer cells: recent innovations in translational innate anti‐cancer immunotherapySemantic proximity Read ↗

Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and ChallengesSemantic proximity Read ↗

Induced Pluripotent Stem Cells: Challenges and Opportunities for Cancer ImmunotherapySemantic proximity Read ↗

Engineered and banked iPSCs for advanced NK- and T-cell immunotherapiesSemantic proximity Read ↗

iPSC-Derived Natural Killer Cells for Cancer ImmunotherapySemantic proximity Read ↗

Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid LeukemiaSemantic proximity Read ↗

Generation of “Off-the-Shelf” Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem CellsSemantic proximity Read ↗

‘Off the shelf’ immunotherapies: Generation and application of pluripotent stem cell‐derived immune cellsSemantic proximity Read ↗

CD33 <sup>KO</sup> -CD33-mesothelin loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.